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CapecitabineAbstract Purpose: Approximately one-third of patients with advanced, HER2+ve breast cancer
(BC) develop brain metastases (BMs). The aim of this study is to investigate efﬁcacy and tolerability
of the combination of lapatinib and capecitabine (LC) in HER2+ve BC patients with brain metas-
tases (BCBM).
Patients and methods: Between January 2011 and January 2013, 21 patients with HER2+ve
BCBM were included. Sixteen patients (76.19%) progressed after whole brain radiotherapy
(WBRT) and 5 patients (23.81%) were treatment-naı¨ve for BM. Patients received lapatinib
(1250 mg/day continuously) and capecitabine (2000 mg/m2 on days 1–14 of a 21-day cycle). All
patients were treated with trastuzumab either in the adjuvant or metastatic setting. No patients
had received prior lapatinib and/or capecitabine. End-points were response rate (RR), progression
free survival (PFS), overall survival (OS) and toxicity.
Results: The overall response rate (ORR) was 33.3% (7/21) and all were partial response. For
patients receiving prior WBRT and patients receiving LC as ﬁrst line treatment for BCBM the
ORR was 31.2% (5/16) and 40.0% (2/5) respectively. Median PFS was 5.5 months. Median OS
was 11 months. Treatment-related adverse events were manageable. Grade 3–4 toxicities were
hand-foot syndrome (14.3%), diarrhea (14.3%), nausea/vomiting (9.5%), mucositis (4.8%), and
skin rash (4.8%).
Conclusion: The combination of LC is active and well-tolerated treatment in patients with
HER2+ve BCBM.
ª 2014 Production and hosting by Elsevier B.V. on behalf of National Cancer Institute, Cairo University.
Open access under CC BY-NC-ND license.Introduction
Worldwide, breast cancer is the most common malignancy and
cause of cancer-related death in women [1,2].
Breast cancer with brain metastases are the second most
frequent secondary CNS metastases being only pre ceded by
188 H. Shawky, H. Tawﬁklung cancer [3]. Its incidence is strongly inﬂuenced by the biol-
ogy of the primary tumor subtype, reaching its highest inci-
dence in HER2-positive and TNBC subtypes and lowest in
the luminal subtypes [4].
Treatment options for patients with brain metastases
include surgery, stereotactic radiosurgery, whole-brain radio-
therapy and steroids [5,6]. The development of effective sys-
temic therapy for recurrent or progressed brain metastases
after local treatment remains a major challenge and an urgent
medical need [7].
The pattern of disease recurrence in the HER2-positive BC
subtype has changed dramatically as a result of the routine use
of adjuvant HER2-directed therapy. The use of adjuvant trast-
uzumab (Herceptin), has not only been effective in reducing
the recurrence rates of HER2-positive breast cancer, but it
has also altered the pattern of relapse and survival following
the diagnosis of BCBM [8,9]. Interestingly, about half of
patients treated with trastuzumab will either be responding
to therapy or have stable disease at the time of diagnosis of
BCBM; the remainder will die of progressive CNS disease
[10]. While trastuzumab is relatively effective in visceral and
bony disease, the brain is increasingly recognized as a sanctu-
ary site for tumor cells due to the relative difﬁculty larger
monoclonal antibody therapies have in penetrating the blood
brain barrier (BBB) [10,11]. Evidence for this comes from the
signiﬁcantly lower cerebrospinal ﬂuid levels of trastuzumab
relative to plasma levels [12,13]. Interestingly, the CSF-to-
serum trastuzumab concentration ratio has been shown to be
improved in the setting of meningeal disease and WBRT [12].
Lapatinib which is a small molecule, has the ability to cross
the BBB and acts as a reversible inhibitor of the intracellular
tyrosine kinase domain of two members of the HER family,
HER1 (EGFR-1) and HER2 (EGFR-2) through binding to
the cytoplasmic ATP-binding site of the kinase and blocks
receptor phosphorylation and activation, thereby preventing
subsequent downstream signaling events [1,10,14].
Lapatinib markedly decreased thymidylate synthase (TS)
expression, thus allowing capecitabine for better inhibition of
the remaining enzyme activity. Additionally, it was suggested
that concomitant administration is more likely to ensure better
efﬁcacy, as compared with sequential use [15].
On the basis of this evidence, we initiated this study to
investigate tolerability and efﬁcacy of the combination of LC
in HER-2 positive BCBM.Patients and methods
Patient eligibility criteria
Between January 2011 and January 2013, 21 patients with brain
metastases HER2-positive BC in the Clinical Oncology Depart-
ment, Faculty of Medicine, Tanta University Hospital were
included. Sixteen patients (76.19%) progressed after WBRT
and 5 patients (23.81%) were treatment-naı¨ve for brain metas-
tases. Brain metastases were conﬁrmed by computed tomogra-
phy scan or magnetic resonance imaging with at least one
measurable brain lesion of a size of 10 mm or greater in diam-
eter. All patients received prior treatment with trastuzumab
either in the adjuvant setting or for the metastatic disease.
Patients fulﬁlled the following criteria: age between 18 and
70 years withHER2+ve (deﬁned as 3+ immunohistochemistryor evidence of gene ampliﬁcation by ﬂuorescence in situ hybrid-
ization) BC, Eastern Cooperative Oncology Group (ECOG)
performance status (PS) of 6 2, adequate bone marrow reserve
(WBC count P3.5 · 109/L, absolute neutrophil count of
P1.5 · 109/L, platelets P100 · 109/L, and hemoglobin
P10 gm/dL), adequate renal function (measured creatinine
clearanceP60 mL/min) and adequate liver function (transami-
nases less than 2 · upper normal limit, and serum bilirubin con-
centrations below 1.5 mg/dL).
Patients suffering from secondary malignancy or concur-
rent serious, uncontrolled medical illness (e.g. persistent
immune-compromised states, uncontrolled infection, severe
peripheral neuropathy, and clinically signiﬁcant cardiac dis-
ease) were excluded from this study. Also patients with prior
exposure to lapatinib or capecitabine, malabsorption or other
gastrointestinal disease affecting absorption of oral medica-
tions, pregnancy or lactation and male sex were excluded.
All radiotherapy, chemotherapy, hormonal therapy, and/or
trastuzumab had to be discontinued at least 2 weeks before ini-
tiation of protocol treatment. Concomitant bisphosphonates,
mannitol, and corticosteroids were allowed, provided that
the corticosteroid dose was stable for at least 1 week before
inclusion.
Design of the study
This study is a prospective single-arm phase II single institu-
tion study. The Ethics Committee in the Faculty of Medicine,
Tanta University, granted protocol approval and all patients
signed an informed consent before the initiation of any
treatment.
Treatment plan and dose medication
Patients received lapatinib 1250 mg once daily every morning
continuously and capecitabine 2000 mg/m2/day, divided into
two doses, on days 1–14, every 21 days.
Cycles were administered on an outpatient basis. Adequate
hematological and within normal range organ functions were
insured prior to each cycle. Chemotherapy was discontinued
in case of disease progression or major toxicities.
Adverse events were monitored throughout the study. A
complete resolution of hematologic and non-hematologic tox-
icity was required except for alopecia and fatigue. If toxicities
did not resolve, then a 1-week delay was allowed.
Patient assessment
Assessment of clinical beneﬁt
A tumor response assessment was performed after every three
cycles of treatment. Pre- and on-treatment monitoring con-
sisted of medical history, physical and neurological examina-
tion, CT-scan of the chest, abdomen and pelvis, and MRI or
CT scan of the brain. Criteria of complete response (CR), par-
tial response (PR), stable disease (SD) and progressive disease
(PD) were based on the standard deﬁnitions according to
RECIST 1.0 criteria [16], with the overall response rate, includ-
ing complete response and partial response. Progression of
non-measurable CNS lesions, tumor-related increase in steroid
dose, new or worsening tumor-related symptoms were consid-
ered as disease progression.
Table 1 Patients’ and tumor characteristics of the 21 patients
with BMs from HER2+ breast cancer treated with LC.
Characteristic No. patients (%)
Age (years)
Mean 45.4
Range (36–69)
ECOG performance status
0 5 (23.8%)
1 10(47.6%)
2 6 (28.6%)
Menopausal status
Pre 14 (66.7%)
Post 7 (33.3%)
Initial tumor grade
Grade I 1 (4.7%)
Grade II 14 (66.7%)
Grade III 6 (28.6%)
Lymph nodes dissected
(median, range) 20 (8–25)
Involved lymph node
(median, range) 7 (0–24)
ER
+ve 14 (66.7%)
-ve 7 (33.3%)
PR
+ve 12 (57.1%)
-ve 9 (42.9%)
ER/PR+ve
Yes 9 (42.9%)
No 12 (57.1%)
Her-2-neu positivity
IHC: 3 + positive 15 (71.4%)
FISH ampliﬁed 6 (28.6%)
Previous systemic therapy
Trastuzumab + endocrine therapy 1 (4.7%)
Trastuzumab + FEC or AC 6 (28.6%)
Trastuzumab + AT 14 (66.7%)
Extracranial metastases
Yes 19 (90.5%)
No 2 (9.5%)
Visceral metastases 16 (76.2%)
Number of BMs
<3 9 (42.9%)
P 3 12 (57.1%)
Local treatment for BMs, n (%)
None 5 (23.8)
Whole cranial radiotherapy 16 (76.2)
ER, estrogen receptors; PR, progesterone receptors; FEC, 5-ﬂou-
orauracil + epirubicin + cyclophosphamide; AT, adriamycin +
taxanes.
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Patients were assessed for adverse events at each site with clin-
ical and laboratory evaluations every 3 weeks and cardiac
monitoring, by ECHO, every 12 weeks. Toxicity grading was
based on the common terminology criteria for adverse events
(NCI-CTC, version 3.0) [17].
Primary and secondary endpoints
The primary endpoints of the study were overall response and
toxicity. Secondary end points were the progression-free sur-
vival and overall survival.
Statistical analysis
Overall-survival (OS) rates were calculated from the start of
the oral combination of LC in HER-2 positive BCBM to the
time of the last follow-up visit or death using the Kaplan–
Meier method [18] with SPSS [Statistical package] (version
12.0). Progression-free survival was the time elapsed from
the date of initiation of oral combination of LC to the date
of ﬁrst evidence of disease progression or death in the absence
of disease progression. Log rank is used for comparison of
curves. Mean and standard deviation were estimates of quan-
titative data. The 95% conﬁdence intervals (95% CIs) were
calculated with the exact method. Fisher exact test was used
for qualitative data. All P values were two-tailed; a value of
6 0.05 was considered signiﬁcant.
Results
Patient characteristics
Twenty-one patients were recruited in the study with patholog-
ically proven HER2+ BC who had developed BMs conﬁrmed
by magnetic resonance imaging or computed tomography
scan. All our patients received at least 2 doses of LC as sys-
temic therapy after the development of BMs.
The base line characteristics are listed in Table 1, with the
mean age 45.4 ± 8.0 years (range; 36–69 years). The majority
of cases were T2 or greater, node positive, grade II, and of
ECOG performance status of 61. Fourteen patients (66.7%)
were premenopausal and 7 patients (33.3%) were postmeno-
pausal. Twelve patients (57.1%) had positive progesterone
receptors (PR), while 14 (66.7%) patients had positive estrogen
receptors (ER), and 9 patients (42.9%) had positive ER and
PR. In 6 patients (28.6%) HER2+ gene ampliﬁcation was con-
ﬁrmed by ﬂuorescence in situ hybridization test. All patients
had received prior trastuzumab-based systemic therapies for
either adjuvant setting or metastatic disease. Local treatment
had been delivered for BMs in 16 patients (76.2%) in the form
of whole cranial radiotherapy (WBRT). Five patients (23.8%)
had not received any prior local treatment for BMs with lapat-
inib and capecitabine (LC) as the ﬁrst systemic option after the
development of BMs in these 5 patients (23.8%).
Treatment administration
A total of 84 chemotherapy cycles were administered. Patients
were treated with a median number of 4 cycles of lapatinib and
capecitabine (range 2–21 cycles).The median treatment duration of lapatinib plus capecitabine
was 12.1 weeks. Themaximum treatment durationwas 63 weeks.
Activity of both drugs (patient response to those drugs)
The overall response rate was 33.3 (7/21) for all patients and no
one had complete response. Stable disease (SD) was recorded in
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Figure 1 Kaplan–Meier curve of progression-free survival.
Median PFS time was 5.5 months.
190 H. Shawky, H. Tawﬁk6 patients (28.6%), while progressive disease (PD) was recorded
in 8 patients (38.1%) (Table 2).
For patients receiving prior cranial radiotherapy (WBRT)
and patients receiving LC as ﬁrst line treatment for BMs the
overall response rate was 31.2% (5/16) and 40.0% (2/5)
respectively.
Toxicity
The LC combination therapy was generally well-tolerated.
Most of the adverse events were of grade 1–2 (Table 3). The
most common grade 3–4 toxicities included hand-foot syn-
drome (14.3%), diarrhea (14.3%), nausea/vomiting (9.5%),
mucositis (4.8%) and rash (4.8%). Grade 3 neutropenia was
observed in one patient. None of the patients developed symp-
tomatic congestive heart failure or an asymptomatic decline in
LVEF to less than 15% of the lower limit of the normal range.
No patient was taken off the treatment because of toxicity and
there was no treatment-related death.
Dose reduction was performed in 6 patients (28.57%) with
25% reduction for both drugs. Chemotherapy was interrupted
for 1 week in 2 patients (9.5%). Five patients received less than
3 cycles due to rapid disease progression.
Survival
Twenty-one patients were recruited in the study between
January 2011 and January 2013. Patients were followed up
until June 2014. At the time of analysis, the median follow
up duration was 11.0 months (Range; 1.57–35.57 months).
All our patients were followed up regularly as mentioned
previously in patients and methods, with no one having lost
follow up in this study.
Median progression free survival (PFS) was 5.ﬁve months
(Range; 1.1–22.0 months), (Fig. 1, Table 4).
Median PFS was 4.1 months, for the 16 (76.2%) patients
for whom prior local treatment had been delivered for BMs
in the form of whole cranial radiotherapy, compared toTable 2 Treatment response on the 21 patients with BMs
from HER2 + breast cancer treated with LC.
Evaluable patients No. %
Partial response 7 33.3
Stable disease 6 28.6
Progressive disease 8 38.1
Table 3 Treatment related adverse events on patients with
BMs from HER2 + breast cancer treated with LC.
Any grade N (%) Grade 3–4 N (%)
Hand-foot syndrome 14 (66.6) 3 (14.3)
Diarrhea 13 (61.9) 3 (14.3)
Nausea/vomiting 11 (52.4) 2 (9.5)
Neutropenia 10 (47.6) 1 (4.8)
Mucositis 8 (38.1) 1 (4.8)
Rash 7 (33.3) 1 (4.8)
Bilirubin increase 5 (23.9) 0.018.3 months, (P =< 0.001), for the 5 (23.8%) patients who
received LC as the ﬁrst therapeutic option after the develop-
ment of BMs, (Fig. 2, Table 4).
Median PFS was 10.5 months, and 3.5 months, for patients
with the number of BMs < 3 and patients with the number of
BMs P 3 respectively (P =< 0.001), (Fig. 3, Table 4).
The median PFS was 6.1 months, compared to 4.1 months,
for the 15 patients with ECOG performance status of 6 1 and
the 6 patients with ECOG performance status of 2 respectively,
(P = 0.141), (Table 4).
The 6 month and 12 month overall survival (OS) for all
patients were 80.6% and 45.6%, respectively, (Fig. 4, Table 5).
The median OS was 9.1 months, for the 16 patients (76.2%)
for whom prior local treatment had been delivered for BMs in
the form of whole cranial radiotherapy. However, the median
OS was not reached, for the 5 patients (23.8%) who had
received LC as the ﬁrst therapeutic option after the develop-
ment of BMs (P =< 0.001), (Table 5).
Median OS was 23.8 months, and 7.1 months, for patients
with the number of BMs < 3 and patients with the number
of BMs P3 respectively, (P =< 0.001), (Fig. 5, Table 5).
The median OS was 11.3 months, and 6.2 months, for the
15 patients with ECOG performance status of 6 1 and the 6
patients with ECOG performance status of 2 respectively,
(P = 0.271), (Table 5).
Discussion
The CNS is an important site for metastatic dissemination
causing substantial morbidity and mortality in patients with
HER2+ BC [4,10,11,19]. Currently, there are limited thera-
peutic options for patients with HER2+ breast cancer who
develop progressive CNS disease after cranial radiotherapy
[7]. So, agents more efﬁcient at penetrating the CNS to prevent
or treat CNS metastases are urgently needed. The use of lapat-
inib with capecitabine (Xeloda) (LC) in treatment of CNS
metastases in patients with HER2+ MBC, has been proved
to improve the response rate and prognosis of patients with
HER2+ BCBM [1,20].
Table 4 Progression free survival of patients with BMs from HER2 + breast cancer treated with LC according to different prognostic
and predictive factors.
Parameter No. of patients (%) Progression free survival p-Value
Median(ms) 6 ms(%) 12 ms(%)
All patients 21 (100) 5.5 42.86 28.57
ECOG performance status
61 15 (71.4) 6.1 51.2 31.7 0.141
2 6 (28.6) 4.1 30.7 20.1
Prior local ttt. for BMs
None 5 (23.8) 18.3 100.0 100.0 <0.001
Whole cranial Rth 16 (76.2) 4.1 31.3 6.3
Hormonal receptors
+ve 14 (66.7) 8.1 61.1 32.9 0.098
-ve 7 (33.3) 5.5 42.9 25.2
Number of BMs
<3 9 (42.9) 10.5 83.3 50.0 <0.001
P3 12 (57.1) 3.5 0.0 0.0
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Figure 2 Kaplan–Meier curve of PFS for the 16 patients for
whom prior whole cranial radiotherapy had been delivered and the
5 patients who received LC as the ﬁrst therapeutic option after the
development of BMs.
Progression free survival in moths
24181260
Su
rv
iv
al
 p
ro
ba
bi
lit
y
1.00
.75
.50
.25
0.00
Number of BMs
>3
>3-censored
<3
<3-censored
Figure 3 Kaplan–Meier curve of PFS for patients with the
number of BMs < 3 and patients with the number of BMs P 3.
All-oral combination of lapatinib and capecitabine in patients with brain metastases 191We used oral lapatinib (1250 mg/day continuously) and
capecitabine (2000 mg/m2 on days 1–14 of a 21-day cycle) con-
tinuously unless there was discontinuation due to severe toxic-
ity or disease progression. This treatment schedules and doses
were selected based on previous studies [19,20].
Our treatment schedule appeared to have good clinical efﬁ-
cacy (33.3%overall response rate). Lin et al. [21] in the lapatinib
plus capecitabine group of his randomized study, reported a
response rate of 38.5% which was comparable with that
reported in a retrospective study of outcome after such combi-
nation treatment (31.8%) [19]. These data are also consistent
with those from analysis of patients with CNS metastasis
included in lapatinib expanded access programmes in the UK
and France [22,23]. This is also consistent with previous pub-
lished study by Cetin et al. [1] who reported a response rate of
27.1%. These results suggest that the combination of lapatinibplus capecitabine has activity for the treatment of brain metas-
tases in patients with HER2-positive breast cancer.
Metro et al. [19] reported that the best response rate (75%)
was remarkably, observed with LC in four patients who had
not received any prior local treatment for BMs. This ﬁnding
might suggest that systemic treatment with LC is active on
BMs in patients who have not been previously treated with
cranial radiotherapy. Similarly, Bachelot et al. [20] observed
that the response rate of 65.9%, (95% CI 50.1–79.5) has been
developed in a trial in which patients received this combination
as their ﬁrst metastatic brain directed therapy and prior to
WBRT. The greater proportion of responses seen in this study
than in other studies [7,21–24] is most likely related to the fact
that this study was restricted to WBRT naive patients. The
current study reported an ORR of 31.2% (5/16), for patients
receiving prior cranial radiotherapy (WBRT) compared to
40.0% (2/5) for patients receiving LC as the ﬁrst line of treat-
ment for BCBM prior to WBRT, supporting the option of
delaying WBRT with its associated toxicities, and instead ini-
tiating a trial of systemic therapy at the time of diagnosis of
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Figure 4 Kaplan–Meier curve of overall survival. Median OS
time was 11 months.
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Figure 5 Kaplan–Meier curve of OS for patients with number of
BMs <3 and P 3.
192 H. Shawky, H. Tawﬁkbrain metastases. This also can allow concomitant treatment of
extra-CNS metastatic sites which can contribute a survival
advantage if cranial disease is controlled [25].
In our study, the median PFS was 5.5 months. Bachelot
et al. [20] reported that the median PFS in published series
on the combination of lapatinib plus capecitabine for the treat-
ment of brain metastases from HER2-positive breast cancer
regimen was 5.5 months [20]. Metro et al. [19] reported that
the combination of chemotherapeutic agents lapatinib plus
capecitabine has been used in the treatment of brain metasta-
ses from HER2-positive breast cancer with a comparable med-
ian PFS of 5.6 months (95% conﬁdence interval 4.4–6.8) in
this patient group. Other trials reported a median PFS of
3.7–5.6 months [7,21–24].
Treatment with lapatinib after the development of BMs was
one of the factors associated with prolonged survival from the
diagnosis of BMs [26]. In our study, the median overall sur-
vival (OS) of 11 months was comparable with that reported
in other trials which published on the OS with lapatinib plus
capecitabine combination which ranged from 6.3 to 13 monthsTable 5 Overall survival of patients with BMs from HER2 + brea
predictive factors.
Parameter No. patients (%) Overa
Media
All patients 21 (100) 11.0
ECOG performance status
61 15 (71.4) 11.3
2 6 (28.6) 6.2
Hormonal receptors
+ve 14 (66.7) 11.3
-ve 7 (33.3) 10.8
Prior local ttt. for BMs
None 5 (23.8) -
Whole cranial Rth 16 (76.2) 9.1
Number of BMs
<3 9 (42.9) 23.8
P3 12 (57.1) 7.1in patients who had received prior trastuzumab combination
therapies [7,21–24].
In our study, this combination therapy was generally well-
tolerated. Most of the adverse events were of grade 1–2. The
most common grade 3–4 toxicities included hand-foot syn-
drome (14.3%), diarrhea (14.3%), nausea/vomiting (9.5%),
mucositis (4.8%) and rash (4.8%). Grade 3 neutropenia was
observed in one patient. None of the patients developed symp-
tomatic congestive heart failure or an asymptomatic decline in
LVEF to less than 15% of the lower limit of the normal range.
There was no treatment-related death. Dose reduction was per-
formed in 6 patients (28.57%) with 25% reduction for both
drugs. Chemotherapy was interrupted for 1 week in 2 patients
(9.5%).The frequency of these toxicities was somewhat lower
than that reported by Bachelot et al. [20] and Sutherland
et al. [22] but higher than that reported in Lin et al. study
[7]. Bachelot et al. [20] reported that about half of patients
had grade 3 or grade 4 toxicities, mainly diarrhea and hand-
foot syndrome, leading to treatment discontinuation in four
patients, without recorded cases of toxic death. Sutherlandst cancer treated with LC according to different prognostic and
ll survival p-Value
n (ms) 6 ms (%) 12 ms (%)
80.6 45.6
85.7 40.8 0.271
57.1 21.4
85.7 42.9 0.827
78.6 40.2
100.0 100.0 <0.001
75.0 26.4
91.7 72.2 <0.001
55.6 0.0
All-oral combination of lapatinib and capecitabine in patients with brain metastases 193et al. [22] reported that serious adverse events (SAEs) in the
overall UK population were again higher with that of our
study. In the UK patients, a total of 25% serious adverse
events were reported. The most frequently reported serious
adverse events were diarrhea, vomiting, nausea, dehydration
and palmar-plantar erythrodysaesthesia syndrome. Also in
the UK study population, two subjects experienced a
decreased ejection fraction and ten serious haepatobiliary
events were reported [22]. In Lin et al. study [7] palmar-plantar
erythrodysesthesia (8%), nausea (8%), vomiting (6%), and
diarrhea (4%) constituted the most common grade 3 adverse
events. However, one fatal serious adverse event was reported
in a patient who died of a small intestinal perforation, but it
was deemed by the treating physician as unrelated to lapatinib
plus capecitabine [7].
Conclusion
From our study, we concluded that the combination of lapat-
inib plus capecitabine (LC) is an active combination against
BMs from HER2+ BC in patients naive for both lapatinib
and capecitabine. Also, our ﬁndings suggest that the combina-
tion of LC may further improve the prognosis in previously
untreated BMs in patients with HER2+ BC. However, head
to head randomized phase 3 studies are advocated to conﬁrm
the clinical beneﬁts for patients in terms of survival, cognitive
function, and quality of life.
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